The FDA Approves Axicabtagene Ciloleucel for R/R Follicular Lymphoma

On March 5, 2021, the U.S. Food and Drug Administration granted accelerated approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma after two or more lines of systemic therapy. 

Read the FDA announcement. Read Kite's announcement.

Posted 3/8/21